Immunosuppressant, Rapamune (Sirolimus), Now Available in Tablet Form in United States
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Immunosuppressant, Rapamune (Sirolimus), Now Available in Tablet Form in United States

MADISON, NJ -- August 2, 2001 -- Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products, announced today that the first solid formulation of its transplant immunosuppressant, Rapamune® (sirolimus), is now available in the United States.
The new 1 mg tablet provides easier administration and storage than Rapamune oral solution.

Rapamune is indicated for the prevention of acute organ rejection in kidney transplant patients and is recommended to be used in a regimen that includes cyclosporine and corticosteroids, which are commonly used in transplant patients. Rapamune was approved in September 1999 as the first in a new class of immunosuppressive agents. It was discovered more than 25 years ago from the soil of Easter Island.

"Rapamune is an important option for renal transplant patients and the tablet form facilitates treatment and storage," says Dr. Harold Marder, Senior Vice President, Medical Affairs, at Wyeth-Ayerst Laboratories. "The availability of a tablet eliminates many of the administration barriers of the oral solution and will be a major enhancement for patients in terms of both convenience and ease of use."

Kidney transplantation is the most common type of transplant procedure in the United States. To help reduce the risk of organ rejection, transplant patients are given a lifelong regimen of immunosuppressant agents. These drugs are intended to lower the body's normal immune response, allowing the transplanted organ to remain functional.

SOURCE: American Home Products

Related Link: American Home Products.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities